Waypoint Bio has secured $20 million in Series A funding, led by Amplify Partners, marking its first major institutional round. The capital infusion will accelerate the development of its AI-powered spatial biology platform for CAR T therapies targeting solid tumors. The round saw participation from General Catalyst, Time BioVentures, Mitsui Global Investments, and Lux Capital, with Elliot Hershberg of Amplify Partners joining the board.
Amount: $20.0M
